Sign in
MBX Stock Price, Chart, Stats & News
MBX Biosciences, Inc. Common Stock
Save
1.69B
Market cap
–
Current P/E
–
Forward P/E
MBX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -22.58% |
ROE | -28.72% |
D/E | 0.00x |
Interest coverage ratio | – |
MBX valuation
P/E | – |
P/S | – |
P/B | 2.82x |
P/CF | -13.01x |
P/FCF | -11.69x |
P/OCF | -13.01x |
PEG | 14.30x |
EV multiple | -10.81x |
About
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism.
Similar securities
Based on sector and market capitalization
Report issue